The University of Zurich (UZH) in Switzerland and its Unispital clinic are cleaning up the stables. Bad doctors made the news, not just one, but several of them, the accusations are of research misconduct, financial embezzlement, patient abuse and who knows what else. UZH and Unispital tried their best to hush everything up, they even sacked a whistleblower, but eventually the Swiss university clinic lost control of the media, which means a lot in Switzerland. It is most unfortunate.
I want to help, as I did before with the cases of the dark chocolate cardiologist Thomas Lüscher, the creative diabetes healers Marc Donath and his PhD student Kathrin Maedler, and more recently, in the Adriano Aguzzi case, a bully and a drama queen who threatened to have me sentenced and jailed for writing about his imaginary PhD degree and the questionable figures in his papers. Here, I proffer to UZH the case of the veterinary medicine professor Michael Hottiger, who also happens to be a close associate of Aguzzi’s. Someone put naughty things in Hottiger’s papers, and I hope the UZH will find and punish the real culprit.
But first, a brief overview of the current media scandal and unsavoury mess for which UZH and Unispital can only blame themselves. In the centre of the affair is the head of Unispital heart surgery clinic, Francesco Maisano.
The affair is best summed up in this paywalled article in Tagesanzeiger, a free-to-read copy was published here. In brief, the whistleblower got sacked, Maisano received unconditional support, and only media reporting forced the Unispital to reconsider their practice.
In late 2019, the heart surgeon Caspar K turned whistleblower and lodged a 42 page report about suspected misconduct by his boss Maisano. 12 heart operations by Maisano and his team were officially reported as success, while the reality was the exact opposite. Incidentally, the media reported already in 2018 about the suspiciously high mortality rates in Maisano’s heart surgery clinic.
In particular, a case of a 74-year-old woman who in 2016 received the heart implant “Cardioband” he developed. It is manufactured by the company Valtech Cardio, which Maisano co-founded, co-owned, used to be Chief Medical Officer with (and still has stakes in), and which was in 2017 sold for $700mn to Edwards Biosciences. Maisano personally received a part of the first tranche of $390 million, a gigantic conflict of interests he omitted, even patients had no clue he was implanting Cardionband while simultaneously receiving gigantic cashflows from his company Valtech. Unispital refuses to say how many millions exactly Maisano received and insist the money didn’t matter to their professor anyway. Only in 2018, after Edwards took over Valtech, was Cardioband revoked. Unispital lawyers saw absolutely no corruption there.
What was worse: the implant failed already during the operation, but Maisano simply edited the video and published the story as success in peer reviewed journals, for example in Maisano et al Eur Heart J 2016. The complications the patient suffered from the torn Cardioband were left out in favour of a fake success story. UZH issued ecstatic press releases, proud to be the only hospital in Switzerland to offer Cardioband implantation. Everyone was happy until Caspar K spoiled the party in Zurich.
The Unispital reacted immediately to the 42 page misconduct dossier. A law firm was tasked with dealing with the matter. Caspar K was offered to immediately depart on sabbatical leave and to sign a non-disclosure agreement. In March 2020, Maisano baselessly accused Caspar K of medical malpractice, several colleagues (incidentally coauthors on the Cardioband papers) supported the accusations. Unispital responded by stripping the whistleblower of operating room access.
In April 2020, the law firm delivered its verdict: Maisano did misrepresent and beautify his data, but no patients were ever endangered. Right after, Caspar K was sacked by Unispital on the spot. On 20 May, Unispital expressed its unconditional support for Maisano. But then, newspaper coverage broke because someone leaked the investigative report. Unispital admitted to journalists that what Maisano did was indeed “research misconduct”, despite the report having determined none whatsoever.
Maisano was suddenly sent on a paid leave for 3 weeks, to organise his defence. Even now, Unispital president Martin Waser commends Maisano for have used his faulty Cardioband implants “sparingly“. UZH and Unispital insist there is no reason at all to involve state prosecutor. In fact, despite there having even been deaths, they insist Maisano did nothing wrong, because, according to Unispital, “the dead patient did not complain”. But the Zurich state prosecutor seems to see it differently.
Two other Unispital doctors also make news. The head of maxillofacial surgery Martin Rücker was ordered to stop re-routing private patients to his private praxis while Unispital pays for the therapies. The head of gynaecology clinic Daniel Fink was also accused of financial misconduct (he managed to get paid for operating 3 patients simultaneously). Whatever he did must have been so bad that Fink was asked to resign “on health reasons”, the investigations continue.
On top of everything, UZH is now part of what may be a gigantic coronavirus-related scientific fraud case: the cardiologist head of Unispital heart clinic Frank Ruschitzka is coauthor on the infamous chloroquine paper Mehra et al Lancet 2020 (read more here), which created a huge impact and is l
ikely steering towards retraction now retracted, with Ruschitzka playing the hapless victim.
With so much going on, Unispital even announced to open an Ombudsman office for whistleblowers, instead of sacking them on the spot.
Update 19.06.2020. Rücker has resigned, officially utterly voluntarily, Maisano is suspended indefinitely while under investigation (including by state prosecutor), with new clinic head already appointed, both of them plus the previously dismissed Fink now became subject to investigation by regional parliament (Kanton). Ruschitzka is now also under a misconduct investigation by UZH, over the Lancet affair.
Now, my humble contribution. No clinical issues here, just some faulty western blots. The victim: UZH and Unispital Professor Dr vet med Michael HotTiger.
“basic principles for dealing with the ethical issues“
Hottiger’s research is about molecular signalling in DNA replication, repair and inflammation, his academic career happened almost exclusively in Zurich, where he was born, and then studied, graduated, and became professor at UZH after a brief pro-forma stint in USA (the trip abroad qualified him as external candidate for the faculty position, a popular practice in many European universities).
In 2017, one Swiss politician wanted to ban painful experiments on primates. The protest campaign was led by Hottiger, his second signatory was Aguzzi (backup of protest letter here). These scientists eventually succeeded in preventing the ban. Hottiger is also president of the Swiss Research for Life foundation (Aguzzi is board member there). This is how they describe the foundation’s purpose (highlight theirs):
“We aim to keep the public informed about the objectives, the importance and the latest results of biomedical research.
We establish the basic principles for dealing with the ethical issues of advances in biomedicine.”
Thus, Professor Hottiger must be the topmost biomedical ethics expert in Switzerland. Let us then look at the papers he published and learn some biomedical ethics, people.
There are in total 10 HotTiger papers on PubPeer, most of the evidence is already 3 years old and as it turned out (see update at the end), it was already investigated by UZH with some, but not much, research misconduct found. Most evidence was flagged by Clare Francis. We shall start with a Nature paper, almost 20 years old.
S Hasan, PO. Hassa, R Imhof, MO. Hottiger Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis Nature (2001) doi: 10.1038/35066610
Something strange happened here. The yellow labelled bands are strangely similar, but the rest of the gel is not. As if someone was copy-pasting them in an old Photoshop version. Maybe something was wrong with the original experimental results, which were not convincing enough for Nature.
S Hasan , N El-Andaloussi , U Hardeland, PO. Hassa, C Bürki, R Imhof, P Schär, MO. Hottiger Acetylation regulates the DNA end-trimming activity of DNA polymerase beta Molecular Cell (2002) doi: 10.1016/s1097-2765(02)00745-1
Molecular Cell is also an elite journal, one where data manipulation is explicitly approved of. Hence, back in 2002 there must have been small print in instructions for authors allowing to recycle and digitally stitch gel images in such creative fashion. Even stranger things happened in the next paper.
CM Simbulan-Rosenthal, DS Rosenthal, R Luo , R Samara , LA Espinoza , PO Hassa , MO Hottiger, ME Smulson PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase Oncogene (2003) doi: 10.1038/sj.onc.1206897
The title of this publication is so long, it even stretched one protein band into three. Maybe the authors disagreed with what that cMyc gel really showed? While Oncogene might show leniency for data irregularities, the following JBC paper will sure get at least corrected, given the publisher’s policies.
PO. Hassa, SS. Haenni, C Buerki, NI. Meier, WS. Lane, H Owen, M Gersbach, R Imhof, MO. Hottiger Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription Journal of Biological Chemistry (2005) doi: 10.1074/jbc.m507553200
Also this EMBO Journal paper might need a correction. Even if it is 15 years old:
M Covic, PO Hassa, S Saccani, C Buerki, NI Meier, C Lombardi, R Imhof, MT Bedford, G Natoli, MO Hottiger Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression The EMBO Journal (2005) doi: 10.1038/sj.emboj.7600500
Again, duplicated gel. How can this keep happening to same UZH authors by mistake?
The next case was tricky, because some PubPeer commenter disagreed the Coomassie loading controls were identical. But the analysis in the PubPeer thread does suggest it.
M Altmeyer , S Messner , PO. Hassa , M Fey , MO. Hottiger Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites Nucleic Acids Research (2009) doi: 10.1093/nar/gkp229
The whole point of the Coomassie loading control is to do it for that very same gel you analyse (here, by a radioactive assay). The journal NAR recently discovered research ethics, so maybe they should have a look.
Here is a double feature:
KM Rothgiesser , M Fey , MO Hottiger Acetylation of p65 at lysine 314 is important for late NF-kappaB-dependent gene expression BMC Genomics (2010) doi: 10.1186/1471-2164-11-22
KM Rothgiesser , S Erener , S Waibel , B Lüscher , MO Hottiger SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310 Journal of Cell Science (2010) doi: 10.1242/jcs.073783
BMC ignored the issue completely, but they sure were aware of the problem. Because a correction was published by J Cell Science in April 2019:
“The authors explained that the data in the two figures validate the specificity of antibodies generated against different acetylated lysines of p65 and originate from the same experiment, meaning that use of the same controls is justified.”
Well, that is OK then. Lazy salami-publishing at best to boost someone’s publication output.
To conclude, a paper coauthored by Hottiger with the infamous Gad Asher as first author, back then in the lab of Ueli Schibler in Geneva. The Israeli biologist Asher has 11 papers on PubPeer flagged for blatant data fakery, it is yet another question if his Weizmann Institute cares about it either way. Or for that matter the elite journal Cell, who are prepared to defend research fraud even against demands from universities. Including in fact even from Weizmann Institute.
G Asher , H Reinke , M Altmeyer , M Gutierrez-Arcelus , MO. Hottiger , U Schibler Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding Cell (2010) doi: 10.1016/j.cell.2010.08.016
Asher commented on PubPeer:
“There is a slight possibility that the original autoradiographs with these negative results (i.e. empty lanes) were kept in Geneva after Ueli’s retirement at the end of 2015. In case we find them, we will look into it. Figure S3 was contributed by our collaborators in Zürich [Hottiger? -LS], and we have contacted them for clarifications. We will provide an in-depth report with the original data in the near future and plan to prepare a correction note for Cell. We sincerely apologize for our negligence in preparing the concerned figures. Best, Gad Asher and Ueli Schibler“
If Weizmann is OK with Asher investigating himself, so be it. But what will UZH do now to help Professor Hottiger fix his old papers?
UZH’s Vice President Faculty Affairs and Scientific Information, Christian Schwarzenegger, wrote to me:
“The accusations on pubpeer against Mr. Hottiger were definitively investigated by the University of Zurich in October / November 2017.
This investigation led to the result that scientific misconduct was excluded in 8 out of 10 publications. For one of the 8 publications, a statement was published in 2019 after consultation with the editor. For two old publications, the raw data could only be partially reconstructed. The scientific evidence of these two publications has since been confirmed by other experiments. As a result of the investigation, Mr. Hottiger was obliged to take the greatest possible care in handling scientific data, which he also confirmed.
There is therefore no reason for the University of Zurich to examine these publications again. We would also like to ask you to remain factual in your comments.“
There are indeed 10 Hottiger papers on PubPeer. Obviously, the corrected one is Rothgiesser et al JCS 2010. If scientific misconduct was excluded in 8 out of 10 papers, it means it was included in the remaining two, with no desire whatsoever for the correction of the published scientific record. I asked Schwarzenegger if anyone checked for raw data with the 8 “non-misconduct” papers, and will update when he replies.
If you are interested to support my work, you can leave here a small tip of $5. Or several of small tips, just increase the amount as you like (2x=€10; 5x=€25). Your generous patronage of my journalism will be most appreciated!
Several years ago, I had an interview with Prof. Hottiger for a potential Ph.D. project under his supervision. After a few minutes, he told me that Ph.D. students in his lab have funding only for the first year. He continued by saying, ‘If you don’t find a fellowship afterward, you’ll leave the lab’. Well…I left his lab immediately.
That could be part of the reason for the relatively high rate of fraud. You only have a year of funding to get a project to work and publish. That’s not a lot of time, and a lot of pressure to either 1.) get a project to work or 2.) make some stuff up to complete a publishable narrative, and get a grant from that, or 3.) completely make ALL of the data up to get a grant.
Sounds like with this policy, he brought this on himself. And he “would have gotten away with it if it wasn’t for those damned failed scientists!” ( a play off a popular TV show in the USA, called Scooby-doo…..)
Had a similar experience with Hottiger when I interviewed for a PhD position in his lab. A very energetic fellow. I left and didn’t look back though when he revealed that he expects his students to go extra miles and sacrifice parts of their private life for his research. Don’t like my boss lecturing me on work ethic.
He repeatidly mentioned that his lab is one of the 3 best labs
worldwide in that particular field. Seems a bit full of himself in the light of this fakery.
That’s what gets you on. You have to make the university believe that you are all that they want, and more. Realists need not apply.
Anticancer Res. 2012 Aug;32(8):3015-27.
Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours
Danielle Boller 1, Kathrin T Doepfner, Angela De Laurentiis, Ana S Guerreiro, Marin Marinov, Tarek Shalaby, Paul Depledge, Anthony Robson, Nahid Saghir, Masahiko Hayakawa, Hiroyuki Kaizawa, Tomonobu Koizumi, Takahide Ohishi, Sarah Fattet, Olivier Delattre, Anelia Schweri-Olac, Katrin Höland, Michael A Grotzer, Karl Frei, Olivier Spertini, Michael D Waterfield, Alexandre Arcaro
1Division of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland.
Mol Biol Cell. 2006 Sep; 17(9): 3729–3744. doi: 10.1091/mbc.E05-11-1083
Phosphoinositide 3-Kinase C2β Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent MechanismsAn external file that holds a picture, illustration, etc.
Object name is dbox.jpgAn external file that holds a picture, illustration, etc.
Object name is vbox.jpg
Roy M. Katso,† Olivier E. Pardo,‡ Andrea Palamidessi,§ Clemens M. Franz, Marin Marinov,‖ Angela De Laurentiis,‖ Julian Downward,‡ Giorgio Scita,§ Anne J. Ridley,¶ Michael D. Waterfield,¶ and Alexandre Arcaro corresponding author‖
Richard Assoian, Monitoring Editor
Author information Article notes Copyright and License information Disclaimer
*Ludwig Institute for Cancer Research, Royal Free and University College Hospital Medical School, London W1W 7BS, United Kingdom;
‡CRUK London Research Institute, London WC2A 3PX, United Kingdom;
§European Institute of Oncology, The FIRC Institute for Molecular Oncology, 20139 Milano, Italy;
‖Division of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, CH-8032 Zurich, Switzerland; and
¶Department of Biochemistry and Molecular Biology, University College London, London WC1E 6BT, United Kingdom
corresponding authorCorresponding author.
Address correspondence to: Alexandre Arcaro (hc.hzinu.ipsik@oracrA.erdnaxelA)
Mol Cancer Res. 2011 Jul;9(7):925-35. doi: 10.1158/1541-7786.MCR-10-0200. Epub 2011 Jun 7.
A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110γ Isoform in Medulloblastoma Cell Proliferation and Chemoresistance
Ana S Guerreiro 1, Sarah Fattet, Dorota W Kulesza, Abdullah Atamer, Alexandra N Elsing, Tarek Shalaby, Shaun P Jackson, Simone M Schoenwaelder, Michael A Grotzer, Olivier Delattre, Alexandre Arcaro
1Department of Oncology, University Children’s Hospital, Zurich, Switzerland.
The left beta-actin panels look very similar in figure 6C Mol Cancer 9,925
and figure 1B Clin Cancer Res 14,6761 look very similar, yet the accompanying p110gamma panels are different.
This is also puzzling
“In the right beta-actin panel figure 6 Mol Cancer Res. 2011 Jul;9(7):925-35 I count 10 bands.
In the right beta-actin panel figure 1B Clin Cancer Res. 2008 Nov 1;14(21):6761-9 I count 11 bands.”
Pingback: Would Lancet and NEJM retractions happen if not for COVID-19 and chloroquine? – For Better Science
Clin Cancer Res. 2013 Jan 1;19(1):96-105. doi: 10.1158/1078-0432.CCR-12-1138. Epub 2012 Nov 21.
Targeting the Phosphoinositide 3-kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer
Anna Wojtalla1, Barbara Fischer3, Nataliya Kotelevets2, Francesco A. Mauri5, Jens Sobek4, Hubert Rehrauer4, Carlos Wotzkow1, Mario P. Tschan1, Michael J. Seckl5, Uwe Zangemeister-Wittke2, and Alexandre Arcaro1,3
Authors’ Affiliations: 1Department of Clinical Research; 2Institute of Pharmacology, University of Bern, Bern; 3Division of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich; 4Functional Genomics Center Zurich, ETH and University of Zurich, Zurich, Switzerland; and 5Lung Cancer Biology Group, Division of Medicine, Imperial College London, London, United Kingdom
Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. CORRELATION WITH RESISTANCE TO ETOPOSIDE-INDUCED APOPTOSIS.
Olivier E. Pardo, Alexandre Arcaro, Giovanni Salerno, Selina Raguz, Julian Downward and Michael J. Seckl
VOLUME 277 (2002) PAGES 12040–12046
This article has been withdrawn by the authors.
Mol Cancer Ther . 2010 Dec;9(12):3145-57. doi: 10.1158/1535-7163.MCT-10-0539. Epub 2010 Oct 1.
The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
Deborah Castelletti 1, Giulio Fiaschetti, Valeria Di Dato, Urs Ziegler, Candy Kumps, Katleen De Preter, Massimo Zollo, Frank Speleman, Tarek Shalaby, Daniela De Martino, Thorsten Berg, Angelika Eggert, Alexandre Arcaro, Michael A Grotzer
1Department of Oncology, University Children’s Hospital of Zurich, Switzerland.
While I appreciate the blog and the detailled overview on the various issues, one should be fair and clarify that Hottiger has nothing to do with the University Hospital (he is not a “Unispital Professor” as stated in the beginning).
In line with that, statement such as “@Unispital_USZ ist ein korrupter Sauladen” are not necessarily helpful but blame hundreds or thousands of innocent employees at the hospital for no reason.
Otherwise, good job in spotting Hottiger’s scientific problems!
True, Hottiger is not affiliated with the Unispital, he is veterinarian after all. My “Sauladen” tweet referred actually to Maisano, Fink, Rücker, Donath, Aguzzi, Lüscher, Ruschitzka, Arcaro and other cases, all current and past clinical affiliates of Unispital. My article is anyway about bad research practices, and hence about the university rather than the hospital.
These gentlemen are in fact all (or used to be) UZH professors and faculty members. In this regard, how UZH managed to convince Swiss media that they have nothing to do with the Maisano affair, is beyond me.
Agree, but I am not sure that the University was successful in “convincing” the media that they have nothing to do with it. My impression is that this is far from being over. They simply have too much to take care of at this point but I would be very surprised if Maisano and Ruecker could hold their positions (these 2 have dominated the headlines in the last weeks, Fink has already been sacked).
Fink was not sacked, he resigned “on health reasons”. The whistleblower Caspar K was sacked, with probably some very nasty things in his reference letter: mistreating patients, troublemaking, slander, sabotage etc.
You see the difference in Caspar K trying to find a new job vs Fink and other doctors who will soon resign on their own accord, with shining reference letters?
The only thing spoiling their career is media reporting, but one can delete Google search results. As it happened to my own site, repeatedly
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5217-22. doi: 10.1073/pnas.0609656104. Epub 2007 Mar 14.
Genetic Deletion of p66(Shc) Adaptor Protein Prevents Hyperglycemia-Induced Endothelial Dysfunction and Oxidative Stress
Giovanni G Camici 1, Marzia Schiavoni, Pietro Francia, Markus Bachschmid, Ines Martin-Padura, Martin Hersberger, Felix C Tanner, Piergiuseppe Pelicci, Massimo Volpe, Piero Anversa, Thomas F Lüscher, Francesco Cosentino
1Cardiology and Cardiovascular Research, University Hospital, Zürich, Switzerland.
Circulation . 2005 Aug 30;112(9):1316-22. doi: 10.1161/CIRCULATIONAHA.105.564112.
Glycogen Synthase kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor-Alpha
Masato Eto 1, Alexei Kouroedov, Francesco Cosentino, Thomas F Lüscher
1Department of Cardiology, Cardiovascular Center, University Hospital, Cardiovascular Research, Institute of Physiology, University of Zurich, Zurich, Switzerland.
Thomas Lüscher you say? Sweet.
Circulation. 2004 Nov 2;110(18):2889-95. doi: 10.1161/01.CIR.0000147731.24444.4D. Epub 2004 Oct 25.
Deletion of p66shc Gene Protects Against Age-Related Endothelial Dysfunction
Pietro Francia 1, Chiara delli Gatti, Markus Bachschmid, Ines Martin-Padura, Carmine Savoia, Enrica Migliaccio, Pier Giuseppe Pelicci, Marzia Schiavoni, Thomas Felix Lüscher, Massimo Volpe, Francesco Cosentino
1Cardiovascular Research & Cardiology, Institute of Physiology, Zürich, Irchel and University Hospital, Zürich, Switzerland.